$Phathom Pharmaceuticals (PHAT.US)$ In a report released today,  from Needham maintained a Buy rating on Phathom Pharmaceuticals ( – ), with a price target of $26.00.
Joseph Stringer has given his Buy rating due to a combination of factors surrounding the recent developments at Phathom Pharmaceuticals. Stringer’s optimism is anchored in the approval of Voquezna for Non-Erosive GERD (NERD), a market considerably larger than the drug’s previous indications. This label expansion is expected to have ...

$Soligenix (SNGX.US)$ shares skyrocketed more than 400% in recent Tuesday trading after the company reported positive results of a study evaluating extended HyBryte treatment in patients with early-stage cutaneous T-cell lymphoma.
The company said six patients were enrolled in the Phase 3 FLASH study and treated with HyBryte over a period of up to 44 weeks, and they responded positively to the therapy with 75% achieving "treatment success."

$Anew Medical (WENA.US)$
ANEW Medical Shares Are Trading Higher After the Company Announced That Is Has Been Granted and Issued a Patent in Europe, EP3377091B1, for the Use of Its Klotho Gene Sequence and Gene Delivery Systems for the Treatment of Diminished Cognition, Memory Loss, Dementia and Other Neurodegenerative Diseases